Characteristic | Did not have sudden death (n = 195) | Had sudden death (n = 13) | P |
---|---|---|---|
Age (y) | 68 ± 11 | 71 ± 11 | 0.454 |
Sex, male | 120 (61.2%) | 10 (76.9%) | 0.379 |
Ischemic etiology | 83 (42.6%) | 6 (46.2%) | 0.782 |
NYHA (baseline), I/II/III/IV | 0/66/108/21 | 0/4/5/4 | 0.792 |
NYHA (follow-up), I/II/III/IV | 38/82/74/1 | 2/4/7/0 | 0.094 |
123I-MIBG scintigraphy | |||
Baseline % denervation | 59 ± 11 | 59 ± 8 | 0.944 |
Baseline H/M ratio | 167 ± 20 | 157 ± 24 | 0.106 |
Baseline WR (%) | 48 ± 11 | 56 ± 9 | 0.008 |
Second % denervation | 51 ± 14 | 66 ± 13 | <0.001 |
Second H/M ratio | 178 ± 24 | 146 ± 22 | <0.001 |
Second WR (%) | 44 ± 12 | 68 ± 8 | <0.001 |
Δ-% denervation | −8 ± 12 | 8 ± 10 | <0.001 |
Δ-H/M ratio | 11 ± 16 | −11 ± 15 | <0.001 |
Δ-WR (%) | −4 ± 11 | 12 ± 10 | <0.001 |
Echocardiography | |||
Baseline LVEDV (mL) | 183 ± 43 | 186 ± 27 | 0.762 |
Baseline LVESV (mL) | 124 ± 41 | 138 ± 37 | 0.241 |
Baseline LVEF (%) | 33 ± 8 | 27 ± 10 | 0.013 |
Second LVEDV (mL) | 167 ± 50 | 199 ± 45 | 0.026 |
Second LVESV (mL) | 106 ± 48 | 145 ± 54 | 0.005 |
Second LVEF (%) | 38 ± 11 | 29 ± 11 | 0.002 |
Δ-LVEDV (mL) | −16 ± 32 | 12 ± 26 | 0.003 |
Δ-LVESV (mL) | −18 ± 32 | 7 ± 23 | 0.005 |
Δ-LVEF (%) | 6 ± 8 | 2 ± 4 | 0.106 |
Pharmacotherapy | |||
ACE inhibitor | 130 (66.7%) | 7 (53.8%) | 0.374 |
ARB | 127 (65.1%) | 7 (53.8%) | 0.551 |
β-blocker | 88 (45.1%) | 4 (30.8%) | 0.313 |
Spironolactone | 77 (39.5%) | 5 (38.5%) | 0.942 |
Values are mean ± SD or number followed by percentage in parentheses.